[目的]探讨SRSF2/tGLI1轴调控Her2阳性乳腺癌侵袭的潜在机制。[方法]在TCGA和GEO数据集(GSE12276、GSE2034、GSE2603、GSE5327、GSE14020)中,分析SRSF2在正常组织和HER2阳性乳腺癌组织中的表达水平以及对无远处转移生存的影响。过表达...[目的]探讨SRSF2/tGLI1轴调控Her2阳性乳腺癌侵袭的潜在机制。[方法]在TCGA和GEO数据集(GSE12276、GSE2034、GSE2603、GSE5327、GSE14020)中,分析SRSF2在正常组织和HER2阳性乳腺癌组织中的表达水平以及对无远处转移生存的影响。过表达或敲低SRSF2或GLI1后,检测HER2阳性乳腺癌细胞SKBR-3、HCC1419、AU-565的侵袭细胞数。敲低SRSF2后分析GLI1的剪接形式,并且过表达GLI1不同剪接形式(fGLI1和tGLI1)后检测HER2阳性乳腺癌细胞的侵袭细胞数。[结果]在TCGA和GEO数据集中,与正常组织相比,HER2阳性乳腺癌组织中SRSF2的mRNA表达上升5倍(1.00±0.05 vs 5.74±0.37,P<0.05)。同时,SRSF2高表达的HER2阳性乳腺癌患者具有更短的无远处转移生存(P<0.05)。过表达SRSF2后,HER2阳性乳腺癌细胞的侵袭细胞数上升2倍(152.88±25.15个vs 376.47±32.31个,P<0.05)。敲低SRSF2后,HER2阳性乳腺癌细胞中fGLI1的mRNA表达上升,tGLI1的mRNA表达下降。过表达tGLI1后,HER2阳性乳腺癌细胞的侵袭细胞数上升3倍(147.43±21.99个vs 397.42±34.03个,P<0.05)。[结论]SRSF2通过选择性剪接将GLI1剪接成tGLI1的形式后,可促进HER2阳性乳腺癌的侵袭能力(152.88±25.15 vs 376.47±32.31,P<0.05)。展开更多
Background Spliceosome mutations have been recently identified and associated with hematological malignancies. SRSF2, one of components of the splicing machinery, has a high mutation frequency during chronic myelomono...Background Spliceosome mutations have been recently identified and associated with hematological malignancies. SRSF2, one of components of the splicing machinery, has a high mutation frequency during chronic myelomonocytic leukemia, according to previous reports. However, the relevance of this finding in Chinese populations remains unknown. Methods We recruited 50 Chinese patients with chronic myelomonocytic leukemia to analyze the state of SRSF2 and to assess the corresponding clinical features by polymerase chain reaction followed by direct sequencing. Results Ten of 50 patients （20%） harbored SRSF2 mutations, including five P95R, two 95H, and three P95L point mutations. The patient group was older than the wild type group （P 〈0.01）. No significant statistical differences were observed with regard to the other clinical characteristics （sex, peripheral blood count, serum lactate dehydrogenase, karyotype, World Health Organization classification, etc.） between these two groups. Two of the patients showed an early evolution to acute myeloid leukemia. Conclusions SRSF2 mutations are frequent in chronic myelomonocytic leukemia patients, but show a relatively lower incidence in Chinese patients. Moreover, the mutation can be related to old age and an unfavorable prognosis. Our results provide valuable insights for the development of a diagnostic marker, or for the identification of a therapeutic target for chronic myelomonocytic leukemia.展开更多
文摘[目的]探讨SRSF2/tGLI1轴调控Her2阳性乳腺癌侵袭的潜在机制。[方法]在TCGA和GEO数据集(GSE12276、GSE2034、GSE2603、GSE5327、GSE14020)中,分析SRSF2在正常组织和HER2阳性乳腺癌组织中的表达水平以及对无远处转移生存的影响。过表达或敲低SRSF2或GLI1后,检测HER2阳性乳腺癌细胞SKBR-3、HCC1419、AU-565的侵袭细胞数。敲低SRSF2后分析GLI1的剪接形式,并且过表达GLI1不同剪接形式(fGLI1和tGLI1)后检测HER2阳性乳腺癌细胞的侵袭细胞数。[结果]在TCGA和GEO数据集中,与正常组织相比,HER2阳性乳腺癌组织中SRSF2的mRNA表达上升5倍(1.00±0.05 vs 5.74±0.37,P<0.05)。同时,SRSF2高表达的HER2阳性乳腺癌患者具有更短的无远处转移生存(P<0.05)。过表达SRSF2后,HER2阳性乳腺癌细胞的侵袭细胞数上升2倍(152.88±25.15个vs 376.47±32.31个,P<0.05)。敲低SRSF2后,HER2阳性乳腺癌细胞中fGLI1的mRNA表达上升,tGLI1的mRNA表达下降。过表达tGLI1后,HER2阳性乳腺癌细胞的侵袭细胞数上升3倍(147.43±21.99个vs 397.42±34.03个,P<0.05)。[结论]SRSF2通过选择性剪接将GLI1剪接成tGLI1的形式后,可促进HER2阳性乳腺癌的侵袭能力(152.88±25.15 vs 376.47±32.31,P<0.05)。
文摘Background Spliceosome mutations have been recently identified and associated with hematological malignancies. SRSF2, one of components of the splicing machinery, has a high mutation frequency during chronic myelomonocytic leukemia, according to previous reports. However, the relevance of this finding in Chinese populations remains unknown. Methods We recruited 50 Chinese patients with chronic myelomonocytic leukemia to analyze the state of SRSF2 and to assess the corresponding clinical features by polymerase chain reaction followed by direct sequencing. Results Ten of 50 patients （20%） harbored SRSF2 mutations, including five P95R, two 95H, and three P95L point mutations. The patient group was older than the wild type group （P 〈0.01）. No significant statistical differences were observed with regard to the other clinical characteristics （sex, peripheral blood count, serum lactate dehydrogenase, karyotype, World Health Organization classification, etc.） between these two groups. Two of the patients showed an early evolution to acute myeloid leukemia. Conclusions SRSF2 mutations are frequent in chronic myelomonocytic leukemia patients, but show a relatively lower incidence in Chinese patients. Moreover, the mutation can be related to old age and an unfavorable prognosis. Our results provide valuable insights for the development of a diagnostic marker, or for the identification of a therapeutic target for chronic myelomonocytic leukemia.
